Cyclophosphamide
EGFR Positive Solid Tumors
Vir Biotechnology, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the EGFR Positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vir-5525 Vir Biotechnology, Inc. | Phase 1 | CC |
Pembrolizumab Vir Biotechnology, Inc. | Phase 1 | CC |
Imgn289 ImmunoGen, Inc. | Phase 1 | CC |
Epirubicin Vir Biotechnology, Inc. | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →